ArticleInternational journal of environmental research and public health2019
The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California.
Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Th2 skewing in patients with disseminated coccidioidomycosis.JCI insight · 2026Article
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Diagnostic Performance of Coccidioidomycosis PCR Testing in Lung Nodules: A Retrospective Study in Central California.Journal of fungi (Basel, Switzerland) · 2025Article
- Type-2 immune skewing in patients with disseminated coccidioidomycosis.medRxiv : the preprint server for health sciences · 2025Article
- The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?Journal of fungi (Basel, Switzerland) · 2025Article
- Article
- The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States.Journal of fungi (Basel, Switzerland) · 2025Article
- Estimating the Exposure-Response Relationship between Fine Mineral Dust Concentration and Coccidioidomycosis Incidence Using Speciated Particulate Matter Data: A Longitudinal Surveillance Study.Environmental health perspectives · 2025Article
- The Known and Unknown "Knowns" of Human Susceptibility to Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Orbital Osteomyelitis and Periorbital Abscess Due to Coccidioidomycosis Following Trauma.Cureus · 2023Article
- Differentiating Lung Nodules Due toJournal of fungi (Basel, Switzerland) · 2023Article
- Article
- Risk of Exposure toMicroorganisms · 2023Article
- Surgical Resection to Treat a Japanese Patient with Pulmonary Coccidioidomycosis.Infection and drug resistance · 2023Article
- Improving Early Recognition of Coccidioidomycosis in Urgent Care Clinics: Analysis of an Implemented Education Program.Open forum infectious diseases · 2023Article
- Immunogenetics associated with severe coccidioidomycosis.JCI insight · 2022Article
- Fluconazole Failure in the Treatment of Coccidioidal Meningitis.Journal of fungi (Basel, Switzerland) · 2022Article
- Natural history of pulmonary coccidioidomycosis: Further examination of the VA-Armed Forces Database.Medical mycology · 2022Article
- Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials.Journal of fungi (Basel, Switzerland) · 2022Review
- Update on the Epidemiology, Diagnosis, and Treatment of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coccidioidomycosis (CM) is a fungal infection endemic in the southwestern United States (US). In California, CM incidence increased more than 213% (from 6.0/100,000 (2014) to 18.8/100,000 (2017)) and continues to increase as rates in the first half of 2018 are double that of 2017 during the same period. This cost-of-illness study provides essential information to be used in health planning and funding as CM infections continue to surge. We used a "bottom-up" approach to determine lifetime costs of 2017 reported incident CM cases in California. We defined CM natural history and used a societal approach to determine direct and discounted indirect costs using literature, national datasets, and expert interviews. The total lifetime cost burden of CM cases reported in 2017 in California is just under $700 million US dollars, with $429 million in direct costs and $271 million in indirect costs. Per person direct costs were highest for disseminated disease ($1,023,730), while per person direct costs were lowest for uncomplicated CM pneumonia ($22,039). Cost burden varied by county. This is the first study to estimate total costs of CM, demonstrating its huge cost burden for California.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.